Retrospective Study: Hip Fractures in Diabetic Patients
NCT ID: NCT01379690
Last Updated: 2012-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1162 participants
OBSERVATIONAL
2011-04-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Increased fall risk may explain why T2DM patients are at increased risk of hip fractures , despite having a higher bone mineral density as compared to non-T2DM patients. Given the high morbidity and mortality (25% mortality in 1st year post-fracture) associated with hip fractures , all care must be given to prevent hip fractures in T2DM patients.
There is controversial data on T2DM medications and fracture risk. Vestergaard showed that use of metformin and sulphonylureas decreased the risk of all fractures, while there was there was a similar trend with insulin.
The present study sought to evaluate the relationship between A1c values and the risk of fractures in treated patients with T2DM.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Type 2 Diabetes and Bone Microarchitecture
NCT04765631
Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population
NCT02797314
Bone Turnover in Type 2 Diabetes and Non-diabetes Controls (DiaMarv)
NCT05585697
A Prospective Cohort Study:Forecast Fracture Risk With a Serum Marker of Type 2 Diabetes in Guangzhou Community
NCT03456271
A1c Discordance in Diabetes Patients
NCT01213277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The information on discharge diagnosis was taken from the Discharge Register of the Hospital. It includes all diagnosis of the patient upon discharge. The diagnosis of patients is coded using the International Classification of Diseases (ICD) system. All patients admitted with the diagnosis of neck of femur fracture (8208 ICD-9), inter-trochanteric fracture (82021 ICD-9), sub-trochanteric fracture (82022 ICD-9), transcervical fracture (82003 ICD-9), and a secondary diagnosis of diabetes (250 ICD-9) were identified from the register.
Out of 932 patients initially identified, 31 were duplicates, 10 were admitted for a traumatic fracture, 136 had no recent A1C level. Of the remaining 757 patients, 162 on diet control and 12 newly diagnosed with diabetes were excluded. The final list of cases consisted of 581 patients, 157 men and 427 women, mean age 76.3 ± 8.7 years.
Controls were selected from a register of patients managed for diabetes from a similar period (1st Jan 2005 to 31st Dec 2010) at Changi General Hospital outpatient clinics (N=4,522). For each case, one control subject, matched for sex and within 2 years of age, was randomly selected from the register. Inclusion criteria included patients taking oral hypoglycemic agents or insulin, and exclusion criteria were patients with a history of hip fractures.
Information on the baseline characteristics and exposure variables were collected by the same methods in cases and control subjects, using the computerised medical records and discernment of the medical notes.
The study was performed in accordance with the Declaration of Helsinki.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
HBA1C
Used level of HBA1C as a reflection of glycaemic control of the cases and controls
Case
All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
HBA1C
Used level of HBA1C as a reflection of glycaemic control of the cases and controls
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HBA1C
Used level of HBA1C as a reflection of glycaemic control of the cases and controls
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hip fracture (Case) or no hip fracture (control)
Exclusion Criteria
* on diet control for diabetes
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changi General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Puar Hai Kiat Troy
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Troy H Puar, MRCP
Role: PRINCIPAL_INVESTIGATOR
Changi General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changi General Hospital
Singapore, Singapore, Singapore
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005 Jul;48(7):1292-9. doi: 10.1007/s00125-005-1786-3. Epub 2005 May 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChangiGH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.